Literature DB >> 20036752

Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.

Ayman Al-Mariri1.   

Abstract

The periplasmic binding protein (P39) antigen of Brucella melitensis 16 M was previously identified as Th1 dominant antigens. In this study, the potential for this antigen to function as vaccine against B. melitensis 16 M infection in BALB/c mice has been analyzed, and the humoral and cellular immune responses induced have been also characterized. Mice were injected intraperitoneally with live Escherichia coli alone or with that which express Brucella P39, two times at 4 weeks intervals. The live E. coli BL21 (DE3) pEt15b-p39 vaccine elicited a T-cell-proliferative response and also induced a gamma interferon production upon re-stimulation with either the bacterial extract or P39 as a specific antigen. Also the live E. coli BL21 (DE3) pEt15b-p39 vaccine has been found to induce a strong humoral response (IgG1 and IgG2a). Compared to the saline-inoculated control, vaccination of mice with E. coli BL21pEt15b-p39 at 3 weeks prior to the challenge infection, significantly reduced the number of strain 16 M bacteria in spleens at 4 and 8 weeks post-challenge infection in all vaccinated mice (p<0.001). Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036752     DOI: 10.1016/j.vaccine.2009.12.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection.

Authors:  Simei Fu; Jie Xu; Xianbo Li; Yongfei Xie; Yefeng Qiu; Xinying Du; Shuang Yu; Yaoxia Bai; Yanfen Chen; Tongkun Wang; Zhoujia Wang; Yaqing Yu; Guangneng Peng; Kehe Huang; Liuyu Huang; Yufei Wang; Zeliang Chen
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

2.  Immune reactivity of sera obtained from brucellosis patients and vaccinated-rabbits to a fusion protein from Brucella melitensis.

Authors:  Jafar Amani; Amir Ghasemi; Reza Ranjbar; Mahdi Shabani; Mahdi Zandemami; Reza Golmohammadi
Journal:  Iran J Basic Med Sci       Date:  2015-04       Impact factor: 2.699

3.  In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate.

Authors:  Amir Ghasemi; Reza Ranjbar; Jafar Amani
Journal:  Iran J Basic Med Sci       Date:  2014-03       Impact factor: 2.699

4.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

Review 5.  Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.

Authors:  Gabriel Gomez; Leslie G Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  Front Cell Infect Microbiol       Date:  2013-05-16       Impact factor: 5.293

6.  Immune reactivity of Brucella melitensis-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins.

Authors:  Amir Ghasemi; Mohammad Hossein Salari; Amir Hassan Zarnani; Mohammad Reza Pourmand; Hojat Ahmadi; Abbas Mirshafiey; Mahmood Jeddi-Tehrani
Journal:  Iran J Microbiol       Date:  2013-03

7.  Evaluation of the immunogenicity and efficacy of a chimeric OMP25-OMP31 antigen in BALB/c mice.

Authors:  Yahya Mohammadi
Journal:  Vet Med Sci       Date:  2021-05-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.